RT Journal Article
SR Electronic
T1 Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20114223
DO 10.1101/2020.05.29.20114223
A1 Wang, Qiang
A1 Guo, Haipeng
A1 Li, Yu
A1 Jian, Xiangdong
A1 Hou, Xinguo
A1 Zhong, Ning
A1 Fei, Jianchun
A1 Su, Dezhen
A1 Bian, Zhouyan
A1 Zhang, Yi
A1 Hu, Yingying
A1 Sun, Yan
A1 Yu, Xueyuan
A1 Li, Yuan
A1 Jiang, Bei
A1 Li, Yan
A1 Qin, Fengping
A1 Wu, Yingying
A1 Gao, Yanxia
A1 Hu, Zhao
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.05.29.20114223.abstract
AB OBJECTIVE To evaluate the safety and efficacy of leflunomide for the treatment of refractory COVID-19 in adult patients.DESIGN Open-label controlled studySETTING A designated hospital for patients with refractory COVID-19 in Wuhan, China.PARTICIPANTS 27 hospitalized adult patients (≥18 years of age) with radiologically confirmed pneumonia and SARS-CoV-2 positive for more than 28 days despite standard care were assigned to receive standard of care (SOC, grp I) or leflunomide + SOC (grp 2). After 2 weeks, grp 1 and grp 2 patients who continued to be SARS-CoV-2-positive received leflunomide for 14 days while continuing SOC.MAIN OUTCOME MEASURES The primary outcomes were the rate of and time to SARS-CoV-2 clearance and the 14-day and 30-day hospital discharge rate.RESULTS Twelve patients enrolled in grp 1 and 15 patients were in grp 2. The 14 days SARS-CoV-2 viral clearance rate was 80.0% (12/15) for grp 2 patients receiving leflunomide versus 16.7% for grp 1 patients (2/12) (P=0.002). By day 14, the median time to SARS-CoV-2 clearance was 6.0 days (range 1-12, IQR 1-12) for grp 2 patients. In grp 1, two patients converted to viral negative on days 1 and 6 (P=0.002). The 14-day discharge rate was 73.3% (11/15) for the grp 2 versus 8.3% (1/12) for grp 1 (P=0.001). The 30-day discharge rate was 100% (15/15) for the grp 2 versus 66.7% (8/12) for grp 1. No severe adverse events or deaths were reported.CONCLUSION Leflunomide is effective in enhancing SARS-CoV-2 clearance and hospital discharge in refractory COVID-19 patients. The addition of leflunomide to SOC did not increase adverse events versus SOC. These preliminary observations underscore a need for a randomized clinical study of leflunomide in SARS-CoV-2 infection.WHAT IS ALREADY KNOWN ON THIS TOPIC Based on the large numbers of global infected patients of SARS-CoV-2, there will be many patients on persist viral positive which is named refractory covid-19. Specific medication for the treatment of the refractory covid-19 has been approved.Leflunomide has been widely used in rheumatoid arthritis and psoriatic arthritis with good safety and tolerance. Recently, it is found an activity of anti-SARS-CoV-2 in vitro and the effective concentration of leflunomide is within the recognized therapeutic level for rheumatoid arthritis.WHAT THIS STUDY ADDS Leflunomide is effective in enhancing SARS-CoV-2 clearance and hospital discharge in refractory COVID-19 patients. The safety and tolerability of the 14-28-day course of treatment with leflunomide is acceptable.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000033372Funding StatementThis work was supported by the COVID-19 Emergency Tackling Research Project of Shandong University (Grant No. 2020XGA 01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Qilu Hospital, Cheeloo College of Medicine, Shandong University (KYLL2020372). All patients gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication, study data will be available on reasonable request to the corresponding author.